PRKG1

cGMP-dependent protein kinase 1 · Q13976 · PRKG1 on Sugi Atlas →

27,858 patent compounds predicted against PRKG1, 18,815 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Linifanib (SCHEMBL93804)	1.00	3/20
Rosoxacin (SCHEMBL135645)	0.48	3/20
SCHEMBL115980	0.55	2/20
SCHEMBL38497	0.50	2/20
SCHEMBL118081	0.46	2/20
SCHEMBL84433	0.41	2/20
Balanol (SCHEMBL62128)	1.00	1/20
Balanol (SCHEMBL62129)	1.00	1/20
SCHEMBL124161	1.00	1/20
Ipatasertib (SCHEMBL191491)	1.00	1/20
Ipatasertib (SCHEMBL191492)	1.00	1/20
Ipatasertib (SCHEMBL191495)	1.00	1/20
Ipatasertib (SCHEMBL191496)	1.00	1/20
Ipatasertib (SCHEMBL191659)	1.00	1/20
Ipatasertib (SCHEMBL191805)	0.98	1/20
Ipatasertib (SCHEMBL192342)	0.98	1/20
SCHEMBL192860	0.85	1/20
SCHEMBL191062	0.84	1/20
SCHEMBL191063	0.84	1/20
SCHEMBL192983	0.84	1/20

Clinical trials — most relevant to PRKG1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
L-arginine Treatment in Mild Hypertension	PHASE4	UNKNOWN
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis	PHASE4	RECRUITING
Bosentan in Treatment of Pulmonary Arterial Hypertension	PHASE4	COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes	PHASE4	COMPLETED
Genetic Factors of Erectile Dysfunction Degree and Response to Tadalafil Treatment in Patients With Diabetes	PHASE3	RECRUITING
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma	PHASE3	COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial	PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease	PHASE2	COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)	PHASE2	COMPLETED
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients	PHASE1/PHASE2	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis	EARLY_PHASE1	RECRUITING
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones	nan	COMPLETED
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis	nan	NOT_YET_RECRUITING
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKG1 binder may also engage these)

Protein	Name	Similarity
P00516	—	1.000	P00516 →
P0C605	—	1.000	P0C605 →
O77676	—	1.000	O77676 →
P31321	—	0.964	P31321 →
P81377	—	0.958	P81377 →
P12849	—	0.957	P12849 →
Q5ZM91	—	0.956	Q5ZM91 →
P00514	—	0.955	P00514 →
P07802	—	0.955	P07802 →
Q9DBC7	—	0.952	Q9DBC7 →
P09456	—	0.951	P09456 →
Q5REL1	—	0.951	Q5REL1 →
P10644	—	0.951	P10644 →
Q5I0F6	—	0.944	Q5I0F6 →
P53033	—	0.935	P53033 →
RFC2	Replication factor C subunit 2	0.925	landscape →
Q05B83	—	0.925	Q05B83 →
Q641W4	—	0.923	Q641W4 →
Q9WUK4	—	0.921	Q9WUK4 →
Q5M786	—	0.914	Q5M786 →
WDR5	WD repeat-containing protein 5	0.913	landscape →
Q8BFY9	—	0.913	Q8BFY9 →
P61965	—	0.912	P61965 →
Q498M4	—	0.912	Q498M4 →
Q2KIG2	—	0.911	Q2KIG2 →
Q5SP67	—	0.910	Q5SP67 →
Q99LG2	—	0.910	Q99LG2 →
P49136	—	0.909	P49136 →
Q58ED9	—	0.909	Q58ED9 →
Q3SYU7	—	0.909	Q3SYU7 →